NCT00675896View on ClinicalTrials.gov

A Study of Quetiapine Fumarate Sustained Release in Major Depression With Comorbid Fibromyalgia Syndrome

PHASE4CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

June 30, 2011

Study Completion Date

July 31, 2011

Conditions
Major Depression
Interventions
DRUG

Quetiapine Fumarate Sustained Release

50 mg/day for the first 2 days and then up to 150mg/day. After two weeks the dose will be doubled up to 300mg at night at the discretion of the investigator

DRUG

Placebo

1 tablet at HS for 2 days then 3 tablets at HS for 2 weeks

Trial Locations (1)

V2A 4M4

Dr. A McIntyre Inc, Penticton

All Listed Sponsors
lead

Dr Alexander McIntyre Inc.

OTHER

NCT00675896 - A Study of Quetiapine Fumarate Sustained Release in Major Depression With Comorbid Fibromyalgia Syndrome | Biotech Hunter | Biotech Hunter